acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
(MEUCPCLKGZSHTA-XYAYPHGZSA-N)
Structure
- SMILES
- OC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N)C)CCCCNC(C)C)CC(C)C)Cc1ccc(cc1)NC(=O)N)Cc1ccc(cc1)NC(=O)[C@@H]1CC(=O)NC(=O)N1)NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](Cc1ccc2c(c1)cccc2)NC(=O)C)Cc1ccc(cc1)Cl)Cc1cccnc1
- Type(s)
- Approved
- ATC code(s)
- L02BX02
- Molecular Formula:
- C82H103ClN18O16
- Molecular Weight:
- 1632.260
- Log P:
- 7.5658
- Hydrogen Bond Acceptor:
- 34
- Hydrogen Bond Donor:
- 17
- TPSA:
- 512.87
- CAS Number(s):
- 214766-78-6
Synonym(s)
1.
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
2.
Ac-2Nal-4Cpa-3Pal-Ser-4Aph(hydroorotyl)-4Aph(carbamoyl)-Leu-ILys-pro-Ala-NH2
3.
FE 200486
4.
FE-200486
5.
FE200486
6.
Firmagon
7.
Gonax
8.
degarelix
9.
uglypeptide1
External Link(s)
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Injection site pain | FAERS: 117 Canada Vigilance: 14 | Canada Vigilance US FAERS | |
| 2 | Injection site erythema | FAERS: 99 Canada Vigilance: 12 | Canada Vigilance US FAERS | |
| 3 | Injection Site Reaction | FAERS: 51 Canada Vigilance: 3 | Canada Vigilance SIDER US FAERS | |
| 4 | Injection site mass | FAERS: 41 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 5 | Pain | FAERS: 34 Canada Vigilance: 7 | Canada Vigilance SIDER US FAERS | |
| 6 | Abdominal Pain | FAERS: 32 Canada Vigilance: 6 | Canada Vigilance SIDER US FAERS | |
| 7 | Chills | FAERS: 31 Canada Vigilance: 8 | Canada Vigilance SIDER US FAERS | |
| 8 | Nausea | FAERS: 30 Canada Vigilance: 8 | Canada Vigilance SIDER US FAERS | |
| 9 | Fatigue | FAERS: 25 Canada Vigilance: 8 | Canada Vigilance SIDER US FAERS | |
| 10 | Myocardial Infarction | FAERS: 22 Canada Vigilance: 6 | Canada Vigilance SIDER US FAERS | |
| 11 | Injection site cellulitis | FAERS: 21 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 12 | Erythema | FAERS: 20 Canada Vigilance: 2 | Canada Vigilance SIDER US FAERS | |
| 13 | Vomiting | FAERS: 20 Canada Vigilance: 3 | Canada Vigilance SIDER US FAERS | |
| 14 | Asthenia | FAERS: 18 Canada Vigilance: 11 | Canada Vigilance SIDER US FAERS | |
| 15 | Cellulitis | FAERS: 17 Canada Vigilance: 4 | Canada Vigilance US FAERS | |
| 16 | Dizziness | FAERS: 17 Canada Vigilance: 9 | Canada Vigilance SIDER US FAERS | |
| 17 | Injection site warmth | FAERS: 17 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 18 | Back Pain | FAERS: 16 Canada Vigilance: 3 | Canada Vigilance SIDER US FAERS | |
| 19 | Incorrect dose administered | FAERS: 16 | US FAERS | |
| 20 | Injection site nodule | FAERS: 16 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 21 | Malaise | FAERS: 16 Canada Vigilance: 7 | Canada Vigilance SIDER US FAERS | |
| 22 | Injection site abscess | FAERS: 13 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 23 | Pneumonia | FAERS: 12 Canada Vigilance: 5 | Canada Vigilance US FAERS | |
| 24 | Pruritus | FAERS: 12 | SIDER US FAERS | |
| 25 | Drug ineffective | FAERS: 11 Canada Vigilance: 12 | Canada Vigilance US FAERS | |
| 26 | Dysuria | FAERS: 11 Canada Vigilance: 5 | Canada Vigilance SIDER US FAERS | |
| 27 | Arthralgia | FAERS: 10 Canada Vigilance: 2 | Canada Vigilance SIDER US FAERS | |
| 28 | Headache | FAERS: 10 Canada Vigilance: 5 | Canada Vigilance SIDER US FAERS | |
| 29 | Incorrect route of drug administration | FAERS: 10 | US FAERS | |
| 30 | Drug dose omission | FAERS: 9 | US FAERS | |
| 31 | Myalgia | FAERS: 9 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 32 | Tremor | FAERS: 9 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 33 | Blood testosterone abnormal | FAERS: 8 | US FAERS | |
| 34 | Injection site discomfort | FAERS: 8 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 35 | Injection site pruritus | FAERS: 8 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 36 | No adverse event | FAERS: 8 | US FAERS | |
| 37 | Weight decreased | FAERS: 8 | SIDER US FAERS | |
| 38 | Bone pain | FAERS: 7 | US FAERS | |
| 39 | Cerebrovascular accident | FAERS: 7 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 40 | Drug administered at inappropriate site | FAERS: 7 | US FAERS | |
| 41 | Hypotension | FAERS: 7 Canada Vigilance: 2 | Canada Vigilance SIDER US FAERS | |
| 42 | Inappropriate schedule of drug administration | FAERS: 7 | US FAERS | |
| 43 | Injection site infection | FAERS: 7 | US FAERS | |
| 44 | Swelling | FAERS: 7 | SIDER US FAERS | |
| 45 | Wrong technique in product usage process | FAERS: 7 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 46 | Abasia | FAERS: 6 | US FAERS | |
| 47 | Injection site inflammation | FAERS: 6 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 48 | Injection site urticaria | FAERS: 6 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 49 | Product administered at inappropriate site | FAERS: 6 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 50 | Product use issue | FAERS: 6 | US FAERS | |
| 51 | Urticaria | FAERS: 6 Canada Vigilance: 1 | Canada Vigilance SIDER US FAERS | |
| 52 | Blood glucose increased | FAERS: 5 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 53 | Blood testosterone increased | FAERS: 5 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 54 | Cardiac Arrest | FAERS: 5 | US FAERS | |
| 55 | Disease Progression | FAERS: 5 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 56 | Erectile dysfunction | FAERS: 5 | SIDER US FAERS | |
| 57 | Feeling Cold | FAERS: 5 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 58 | Hypersensitivity | FAERS: 5 | SIDER US FAERS | |
| 59 | Musculoskeletal Pain | FAERS: 5 Canada Vigilance: 1 | Canada Vigilance SIDER US FAERS | |
| 60 | Product dose omission | FAERS: 5 | US FAERS | |
| 61 | Urinary Retention | FAERS: 5 | US FAERS | |
| 62 | Urinary tract infection | FAERS: 5 Canada Vigilance: 3 | Canada Vigilance SIDER US FAERS | |
| 63 | Wrong technique in drug usage process | FAERS: 5 | US FAERS | |
| 64 | Discomfort | FAERS: 4 Canada Vigilance: 2 | Canada Vigilance SIDER US FAERS | |
| 65 | Drug administration error | FAERS: 4 | US FAERS | |
| 66 | Infection | FAERS: 4 Canada Vigilance: 5 | Canada Vigilance US FAERS | |
| 67 | Inflammation | FAERS: 4 | SIDER US FAERS | |
| 68 | Injection site bruising | FAERS: 4 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 69 | Intentional drug misuse | FAERS: 4 | US FAERS | |
| 70 | Lethargy | FAERS: 4 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 71 | Pallor | FAERS: 4 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 72 | Palpitations | FAERS: 4 Canada Vigilance: 2 | Canada Vigilance SIDER US FAERS | |
| 73 | Peripheral swelling | FAERS: 4 Canada Vigilance: 5 | Canada Vigilance US FAERS | |
| 74 | Product lot number issue | FAERS: 4 | US FAERS | |
| 75 | Sepsis | FAERS: 4 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 76 | Syncope | FAERS: 4 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 77 | Abdominal discomfort | FAERS: 3 | SIDER US FAERS | |
| 78 | Abdominal mass | FAERS: 3 | US FAERS | |
| 79 | Adverse event | FAERS: 3 | US FAERS | |
| 80 | Amnesia | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 81 | Aspartate Aminotransferase Increased | FAERS: 3 | US FAERS | |
| 82 | Atrial Fibrillation | FAERS: 3 | SIDER US FAERS | |
| 83 | Burning sensation | FAERS: 3 | US FAERS | |
| 84 | Chest Pain | FAERS: 3 | US FAERS | |
| 85 | Diabetes Mellitus | FAERS: 3 | SIDER US FAERS | |
| 86 | Feeling abnormal | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance SIDER US FAERS | |
| 87 | General physical health deterioration | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 88 | Incorrect drug administration rate | FAERS: 3 | US FAERS | |
| 89 | Injection site irritation | FAERS: 3 | US FAERS | |
| 90 | Injection site scar | FAERS: 3 | US FAERS | |
| 91 | Monoplegia | FAERS: 3 | US FAERS | |
| 92 | Nodule | FAERS: 3 | SIDER US FAERS | |
| 93 | Product solubility abnormal | FAERS: 3 | US FAERS | |
| 94 | Pulmonary Embolism | FAERS: 3 | US FAERS | |
| 95 | Shock | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 96 | Sudden death | FAERS: 3 | US FAERS | |
| 97 | Urinary tract obstruction | FAERS: 3 | US FAERS | |
| 98 | Abscess | FAERS: 2 | SIDER US FAERS | |
| 99 | Acute kidney injury | FAERS: 2 | US FAERS | |
| 100 | Acute myocardial infarction | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 101 | Alanine Aminotransferase Increased | FAERS: 2 | US FAERS | |
| 102 | Altered state of consciousness | FAERS: 2 | US FAERS | |
| 103 | Amputation | FAERS: 2 | US FAERS | |
| 104 | Anaphylactoid Reaction | FAERS: 2 | US FAERS | |
| 105 | Angina Pectoris | FAERS: 2 | US FAERS | |
| 106 | Angioedema | FAERS: 2 | US FAERS | |
| 107 | Blood alkaline phosphatase increased | FAERS: 2 | SIDER US FAERS | |
| 108 | Blood testosterone decreased | FAERS: 2 | US FAERS | |
| 109 | Blood urine present | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 110 | Cerebral Infarction | FAERS: 2 | US FAERS | |
| 111 | Cholestasis | FAERS: 2 | US FAERS | |
| 112 | Cold sweat | FAERS: 2 | US FAERS | |
| 113 | Constipation | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance SIDER US FAERS | |
| 114 | Deep Vein Thrombosis | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 115 | Dehydration | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 116 | Device related infection | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 117 | Expired product administered | FAERS: 2 | US FAERS | |
| 118 | Flushing | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 119 | Gamma-Glutamyltransferase Increased | FAERS: 2 | US FAERS | |
| 120 | Hemiparesis | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 121 | Hypertensive crisis | FAERS: 2 | US FAERS | |
| 122 | Infarction | FAERS: 2 | US FAERS | |
| 123 | Injection site hypersensitivity | FAERS: 2 | US FAERS | |
| 124 | Injury associated with device | FAERS: 2 | US FAERS | |
| 125 | Lymphoma | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 126 | Medication Error | FAERS: 2 | US FAERS | |
| 127 | Memory impairment | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 128 | Occupational exposure to product | FAERS: 2 | US FAERS | |
| 129 | Osteoporosis | FAERS: 2 | SIDER US FAERS | |
| 130 | Post procedural complication | FAERS: 2 | US FAERS | |
| 131 | Product preparation error | FAERS: 2 | US FAERS | |
| 132 | Product quality issue | FAERS: 2 | US FAERS | |
| 133 | Product storage error | FAERS: 2 | US FAERS | |
| 134 | Product use in unapproved indication | FAERS: 2 | US FAERS | |
| 135 | Syringe issue | FAERS: 2 | US FAERS | |
| 136 | Thrombosis | FAERS: 2 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 137 | Unevaluable event | FAERS: 2 | US FAERS | |
| 138 | Unresponsive to stimuli | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 139 | Urethral Stenosis | FAERS: 2 | US FAERS | |
| 140 | jaundice | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 141 | Abdominal Abscess | FAERS: 1 | US FAERS | |
| 142 | Abdominal rigidity | FAERS: 1 | US FAERS | |
| 143 | Abdominal tenderness | FAERS: 1 | US FAERS | |
| 144 | Accidental exposure to product | FAERS: 1 | US FAERS | |
| 145 | Accidental exposure | FAERS: 1 | US FAERS | |
| 146 | Accidental overdose | FAERS: 1 | US FAERS | |
| 147 | Acne | FAERS: 1 | US FAERS | |
| 148 | Acute Coronary Syndrome | FAERS: 1 | SIDER US FAERS | |
| 149 | Agitation | FAERS: 1 | US FAERS | |
| 150 | Anaphylactic shock | FAERS: 1 | SIDER US FAERS | |
| 151 | Antiandrogen therapy | FAERS: 1 | US FAERS | |
| 152 | Anuria | FAERS: 1 | US FAERS | |
| 153 | Anxiety | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 154 | Appendicitis | FAERS: 1 | US FAERS | |
| 155 | Arthropathy | FAERS: 1 | US FAERS | |
| 156 | Ascites | FAERS: 1 | US FAERS | |
| 157 | Asthma | FAERS: 1 | US FAERS | |
| 158 | Atrioventricular conduction time shortened | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 159 | Bedridden | FAERS: 1 | US FAERS | |
| 160 | Bladder Neoplasm | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 161 | Bladder sphincter atony | FAERS: 1 | US FAERS | |
| 162 | Blood glucose abnormal | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 163 | Blood glucose fluctuation | FAERS: 1 | US FAERS | |
| 164 | Blood potassium increased | FAERS: 1 | US FAERS | |
| 165 | Blood sodium abnormal | FAERS: 1 | US FAERS | |
| 166 | Cardiac Death | FAERS: 1 | US FAERS | |
| 167 | Cataract operation | FAERS: 1 | US FAERS | |
| 168 | Cataract | FAERS: 1 | US FAERS | |
| 169 | Chemotherapy | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 170 | Chest discomfort | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 171 | Choking | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 172 | Cholelithiasis | FAERS: 1 | US FAERS | |
| 173 | Colitis | FAERS: 1 | US FAERS | |
| 174 | Creatinine renal clearance decreased | FAERS: 1 | US FAERS | |
| 175 | Cystitis | FAERS: 1 | US FAERS | |
| 176 | Deafness | FAERS: 1 | US FAERS | |
| 177 | Delirium | FAERS: 1 | US FAERS | |
| 178 | Dementia | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 179 | Depressed Level of Consciousness | FAERS: 1 | US FAERS | |
| 180 | Depressed mood | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 181 | Device occlusion | FAERS: 1 | US FAERS | |
| 182 | Diabetes mellitus inadequate control | FAERS: 1 | US FAERS | |
| 183 | Diaphragmalgia | FAERS: 1 | US FAERS | |
| 184 | Diplopia | FAERS: 1 | US FAERS | |
| 185 | Diverticulitis | FAERS: 1 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 186 | Drug effect delayed | FAERS: 1 | US FAERS | |
| 187 | Dysarthria | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 188 | Dyspepsia | FAERS: 1 | US FAERS | |
| 189 | Epistaxis | FAERS: 1 | US FAERS | |
| 190 | Exposure via skin contact | FAERS: 1 | US FAERS | |
| 191 | Flank Pain | FAERS: 1 | US FAERS | |
| 192 | Flatulence | FAERS: 1 | US FAERS | |
| 193 | Gait inability | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 194 | General physical condition abnormal | FAERS: 1 | US FAERS | |
| 195 | Hepatitis | FAERS: 1 | US FAERS | |
| 196 | Hydronephrosis | FAERS: 1 | US FAERS | |
| 197 | Ileus | FAERS: 1 | US FAERS | |
| 198 | Inappropriate schedule of product administration | FAERS: 1 | US FAERS | |
| 199 | Incontinence | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance SIDER US FAERS | |
| 200 | Incorrect drug administration duration | FAERS: 1 | US FAERS | |
| 201 | Incorrect route of product administration | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 202 | Induration | FAERS: 1 | SIDER US FAERS | |
| 203 | Infusion site granuloma | FAERS: 1 | US FAERS | |
| 204 | Injection site coldness | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 205 | Injection site cyst | FAERS: 1 | US FAERS | |
| 206 | Injection site discharge | FAERS: 1 | US FAERS | |
| 207 | Injection site extravasation | FAERS: 1 | US FAERS | |
| 208 | Injection site necrosis | FAERS: 1 | US FAERS | |
| 209 | Injection site papule | FAERS: 1 | US FAERS | |
| 210 | Intentional product misuse | FAERS: 1 | US FAERS | |
| 211 | Intentional product use issue | FAERS: 1 | US FAERS | |
| 212 | Intercepted drug prescribing error | FAERS: 1 | US FAERS | |
| 213 | Joint Instability | FAERS: 1 | US FAERS | |
| 214 | Laceration | FAERS: 1 | US FAERS | |
| 215 | Large intestine perforation | FAERS: 1 | US FAERS | |
| 216 | Lip swelling | FAERS: 1 | US FAERS | |
| 217 | Lymphadenopathy | FAERS: 1 | US FAERS | |
| 218 | Male genital examination abnormal | FAERS: 1 | US FAERS | |
| 219 | Medical device complication | FAERS: 1 | US FAERS | |
| 220 | Mental impairment | FAERS: 1 | US FAERS | |
| 221 | Mental status changes | FAERS: 1 | US FAERS | |
| 222 | Muscle Rigidity | FAERS: 1 | US FAERS | |
| 223 | Muscle tightness | FAERS: 1 | US FAERS | |
| 224 | Musculoskeletal chest pain | FAERS: 1 | US FAERS | |
| 225 | Musculoskeletal discomfort | FAERS: 1 | SIDER US FAERS | |
| 226 | Nasopharyngitis | FAERS: 1 | US FAERS | |
| 227 | Needle issue | FAERS: 1 | US FAERS | |
| 228 | Nephrolithiasis | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 229 | Nervousness | FAERS: 1 | US FAERS | |
| 230 | Neuralgia | FAERS: 1 | US FAERS | |
| 231 | Night sweats | FAERS: 1 | SIDER US FAERS | |
| 232 | Nocturia | FAERS: 1 | SIDER US FAERS | |
| 233 | Overdose | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 234 | Pancytopenia | FAERS: 1 | US FAERS | |
| 235 | Pathological fracture | FAERS: 1 | US FAERS | |
| 236 | Pelvic Pain | FAERS: 1 | SIDER US FAERS | |
| 237 | Penile size reduced | FAERS: 1 | US FAERS | |
| 238 | Peripheral embolism | FAERS: 1 | US FAERS | |
| 239 | Personal relationship issue | FAERS: 1 | US FAERS | |
| 240 | Physical disability | FAERS: 1 | US FAERS | |
| 241 | Pneumoperitoneum | FAERS: 1 | US FAERS | |
| 242 | Polyuria | FAERS: 1 | US FAERS | |
| 243 | Poor quality product administered | FAERS: 1 | US FAERS | |
| 244 | Presyncope | FAERS: 1 | US FAERS | |
| 245 | Procedural hypotension | FAERS: 1 | US FAERS | |
| 246 | Product administration error | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 247 | Product availability issue | FAERS: 1 | US FAERS | |
| 248 | Product closure issue | FAERS: 1 | US FAERS | |
| 249 | Product preparation issue | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 250 | Product prescribing error | FAERS: 1 | US FAERS | |
| 251 | Productive Cough | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 252 | Prostatic specific antigen decreased | FAERS: 1 | US FAERS | |
| 253 | Pulmonary congestion | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 254 | Pulmonary thrombosis | FAERS: 1 | US FAERS | |
| 255 | Pyelonephritis | FAERS: 1 | US FAERS | |
| 256 | Refusal of treatment by relative | FAERS: 1 | US FAERS | |
| 257 | Renal tubular necrosis | FAERS: 1 | US FAERS | |
| 258 | Respiratory Failure | FAERS: 1 | US FAERS | |
| 259 | Respiratory arrest | FAERS: 1 | US FAERS | |
| 260 | Respiratory distress | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 261 | Retching | FAERS: 1 | US FAERS | |
| 262 | Selective eating disorder | FAERS: 1 | US FAERS | |
| 263 | Septic Shock | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 264 | Skin irritation | FAERS: 1 | US FAERS | |
| 265 | Skin lesion | FAERS: 1 | US FAERS | |
| 266 | Skin reaction | FAERS: 1 | US FAERS | |
| 267 | Somnolence | FAERS: 1 | US FAERS | |
| 268 | Squamous cell carcinoma of skin | FAERS: 1 | US FAERS | |
| 269 | Staphylococcal abscess | FAERS: 1 | US FAERS | |
| 270 | Staphylococcus test positive | FAERS: 1 | US FAERS | |
| 271 | Subcutaneous Abscess | FAERS: 1 | US FAERS | |
| 272 | Sudden Cardiac Death | FAERS: 1 | US FAERS | |
| 273 | Terminal state | FAERS: 1 | US FAERS | |
| 274 | Thalamic infarction | FAERS: 1 | US FAERS | |
| 275 | Therapeutic response unexpected | FAERS: 1 | US FAERS | |
| 276 | Thrombotic stroke | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 277 | Ureteral stent insertion | FAERS: 1 | US FAERS | |
| 278 | Urinary Incontinence | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 279 | Urinary Tract Pain | FAERS: 1 | US FAERS | |
| 280 | Urinary hesitation | FAERS: 1 | US FAERS | |
| 281 | Urine flow decreased | FAERS: 1 | US FAERS | |
| 282 | Vertebrobasilar Insufficiency | FAERS: 1 | US FAERS | |
| 283 | Vertigo | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 284 | Waist circumference increased | FAERS: 1 | US FAERS | |
| 285 | Wrong patient received medication | FAERS: 1 | US FAERS | |
| 286 | furuncle | FAERS: 1 | US FAERS | |
| 287 | nervous system disorder | FAERS: 1 | SIDER US FAERS | |
| 288 | Administration site hypersensitivity | Canada Vigilance: 1 | Canada Vigilance | |
| 289 | Administration site infection | SIDER | ||
| 290 | Alopecia | SIDER | ||
| 291 | Blood and lymphatic system disorders | SIDER | ||
| 292 | Blood glucose decreased | Canada Vigilance: 1 | Canada Vigilance | |
| 293 | Bone density decreased | SIDER | ||
| 294 | Bradycardia | Canada Vigilance: 1 | Canada Vigilance | |
| 295 | Cardiac procedure complication | Canada Vigilance: 1 | Canada Vigilance | |
| 296 | Dermatitis | SIDER | ||
| 297 | Disturbance in sexual arousal | SIDER | ||
| 298 | Electrocardiogram U wave present | SIDER | ||
| 299 | Electrocardiogram U-wave abnormality | SIDER | ||
| 300 | Electrocardiogram change | SIDER | ||
| 301 | Embolism | Canada Vigilance: 1 | Canada Vigilance | |
| 302 | Febrile Neutropenia | SIDER | ||
| 303 | Gastrointestinal Pain | SIDER | ||
| 304 | Genital discomfort | SIDER | ||
| 305 | Genital irritation | SIDER | ||
| 306 | Hip surgery | Canada Vigilance: 1 | Canada Vigilance | |
| 307 | Incision site pain | Canada Vigilance: 2 | Canada Vigilance | |
| 308 | Incoherent | Canada Vigilance: 1 | Canada Vigilance | |
| 309 | Injection site streaking | Canada Vigilance: 1 | Canada Vigilance | |
| 310 | Joint swelling | SIDER | ||
| 311 | Malignant neoplasm progression | Canada Vigilance: 2 | Canada Vigilance | |
| 312 | Malnutrition | SIDER | ||
| 313 | Mental Retardation | SIDER | ||
| 314 | Mood swings | Canada Vigilance: 1 | Canada Vigilance | |
| 315 | Musculoskeletal stiffness | SIDER | ||
| 316 | Oropharyngeal pain | Canada Vigilance: 1 | Canada Vigilance | |
| 317 | Osteopenia | SIDER | ||
| 318 | Pain management | Canada Vigilance: 1 | Canada Vigilance | |
| 319 | Skin laceration | Canada Vigilance: 1 | Canada Vigilance | |
| 320 | Skin nodule | SIDER | ||
| 321 | Stiffness | SIDER | ||
| 322 | Tooth Infection | Canada Vigilance: 1 | Canada Vigilance | |
| 323 | Transaminases increased | SIDER | ||
| 324 | White blood cell count decreased | Canada Vigilance: 1 | Canada Vigilance | |
| 325 | treatment failure | Canada Vigilance: 1 | Canada Vigilance |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.